Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 44 results for prostatectomy

  1. Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]

    Awaiting development Reference number: GID-TA11490 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Focal therapy using cryoablation for localised prostate cancer (HTG284)

    Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.

    HealthTech guidance
    Published
    26 April 2012
    View recommendations

    Sections for HTG284

  3. PLASMA system with button electrode for electrovaporisation of the prostate (MIB274)

    NICE has developed a medtech innovation briefing (MIB) on PLASMA system with button electrode for electrovaporisation of the prostate .

    Medtech innovation briefing
    Published
    31 August 2021

  4. Robot-assisted surgery for soft tissue procedures: early value assessment (HTG742)

    Early value assessment (EVA) guidance on robot-assisted surgery for soft tissue procedures.

    HealthTech guidance
    Published
    17 April 2025
    View recommendations

    Sections for HTG742

  5. Axumin for functional imaging of prostate cancer recurrence (MIB172)

    NICE has developed a medtech innovation briefing (MIB) on Axumin for functional imaging of prostate cancer recurrence .

    Medtech innovation briefing
    Published
    8 February 2019

  6. Transperineal template biopsy and mapping of the prostate (HTG237)

    Evidence-based recommendations on transperineal template biopsy of the prostate. This involves inserting many fine needles though the skin between the scrotum and the anus in order to obtain tissue samples from the prostate for testing.

    HealthTech guidance
    Published
    27 October 2010
    View recommendations

    Sections for HTG237

  7. Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (HTG482)

    Evidence-based recommendations on transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults. This involves using heated water vapour to destroy some of the prostate tissue.

    HealthTech guidance
    Published
    21 August 2018
    View recommendations

    Sections for HTG482

  8. Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia (HTG469)

    Evidence-based recommendations on prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults. This involves blocking the blood vessels supplying the prostate with tiny plastic particles.

    HealthTech guidance
    Published
    25 April 2018
    View recommendations

    Sections for HTG469

  9. Cryotherapy for recurrent prostate cancer (HTG71)

    Evidence-based recommendations on cryotherapy for treating recurrent prostate cancer. This involves putting special needles or probes into the prostate and using Argon gas to freeze and destroy the cancerous prostate tissue.

    HealthTech guidance
    Published
    25 May 2005
    View recommendations

    Sections for HTG71

  10. Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (HTG691)

    Evidence-based recommendations on transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves injecting a high-speed jet of water into the prostate to destroy some of the prostate tissue and widen the urethra.

    HealthTech guidance
    Published
    14 September 2023
    View recommendations

    Sections for HTG691

  11. Focal therapy using high-intensity focused ultrasound for localised prostate cancer (HTG667)

    Evidence-based recommendations on focal therapy using high-intensity focused ultrasound for localised prostate cancer. This involves using high-intensity focused ultrasound to heat up and destroy only the areas of the prostate with cancer (focal therapy). The aim is to destroy the cancer while reducing damage to healthy prostate tissue.

    HealthTech guidance
    Published
    5 April 2023
    View recommendations

    Sections for HTG667

  12. Prolaris gene expression assay for assessing long-term risk of prostate cancer progression (MIB65)

    NICE has developed a medtech innovation briefing (MIB) on the Prolaris gene expression assay for assessing long-term risk of prostate cancer progression

    Medtech innovation briefing
    Published
    24 May 2016

  13. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (HTG639)

    Evidence-based recommendations on prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves positioning a temporary implant in the urethra to increase the flow of urine.

    HealthTech guidance
    Published
    21 September 2022
    View recommendations

    Sections for HTG639

  14. Irreversible electroporation for treating prostate cancer (HTG688)

    Evidence-based recommendations on irreversible electroporation for treating prostate cancer. This involves using electrical pulses to destroy the cancer cells.

    HealthTech guidance
    Published
    5 July 2023
    View recommendations

    Sections for HTG688

  15. GreenLight XPS for treating benign prostatic hyperplasia (HTG650)

    Evidence-based recommendations on GreenLight XPS for treating benign prostatic hyperplasia.

    HealthTech guidance
    Published
    29 November 2022
    View recommendations

    Sections for HTG650